Pain Points and Progress: Navigating the Complexities of Life Sciences Logistics
Vincent Howard, CEO, Biocair
Rising geopolitical tensions and trade wars are adding to the complexity in the life sciences supply chain. This article looks at how logistics teams are tackling these challenges, from geopolitical instability and trade pressures to economic and environmental hurdles, all while maintaining regulatory and customs compliance.
Introduction:
Within recent years, there has been a new facet of complexity in the supply chain pathways of the life sciences industry. From rising geopolitical tensions to trade wars, logistics teams now have to operate in an environment shaped by rapid change, regulatory scrutiny, and unpredictable policy changes influenced by politics.
For the life sciences sector, including pharmaceuticals, biotech, and medical device manufacturing, the stakes are especially high. These companies not only rely on a highly globalised supply chain, but they also move temperature-sensitive, high-value, and often life-saving products across borders. With healthcare systems under increasing strain, drug development costs rising, and supply chain expenses ultimately passed on to patients, any disruption can ripple through the system with significant health and financial consequences.
Geopolitical Instability and Trade Pressures
Tariffs, taxes, and duties significantly increase costs for imported goods, including critical pharmaceutical ingredients and medical devices. These additional expenses may be passed on to patients or product consumers, particularly with high-cost items like specialised medical equipment or new medicines, negatively affecting the accessibility of healthcare products. Furthermore, in a highly regulated industry, shifting trade rules not only affect price but can also introduce delays, require costly product reclassifications, and force sudden changes to sourcing strategies. For temperature-sensitive products, even a short delay at customs can lead to spoilage, loss, or compliance breaches.
Complicating matters further, geopolitical tensions, changing international relationships and volatile trade policies present a mounting challenge for life sciences supply chains.
To mitigate these risks, companies are exploring onshoring, which is the strategy of relocating manufacturing closer to key markets. This can increase control and reduce dependency on international partners; however, this comes with significant challenges: upfront investment in infrastructure, long timelines for regulatory approvals, and the complexity of transferring validated manufacturing processes across borders. As such, many organisations now face a tough decision: invest in domestic capacity now, or adopt a cautious, wait-and-see approach in an uncertain global environment.
Economic Challenges
The broader economic landscape and potential recession add further challenges, making investors more cautious, and small-to-mid-sized biotech firms, which are often reliant on tight development timelines and narrow funding windows, particularly vulnerable.
Shipping delays due to being held at customs or product losses in transit can set clinical timelines back by months and result in unplanned costs that are hard to recover. As a result, the demand on logistics providers for reliability and predictability has never been higher.
Navigating duties, tariffs, and taxes effectively is also a crucial part of economic risk management. By remaining aware of and leveraging free trade agreements, life sciences companies can reduce the impact of tariffs and taxes. Moreover, proper product classification under the Harmonised System (HS) codes can help avoid unnecessary overpayment or penalties. Lastly, exploring strategies like tariff engineering, where companies may redesign products or change their manufacturing processes slightly to reduce the duty rate or tariff impact, can be a method to proactively reduce the financial risks of cross-border trade. Equally important is the need for a flexible, multi-sourced supply chain that can adapt quickly to policy changes or supplier disruptions, to reduce reliance on any single country or supplier in the case of unexpected tariffs or duties.
Environmental Impact
Sustainability, while sometimes overshadowed by short-term operational logistics, remains a central goal for the life sciences sector. Given its strong foundation in scientific evidence and public health, the industry is under increasing pressure to meet environmental targets around Scope 3 emissions, which includes all indirect greenhouse emissions within the whole supply chain.
Transportation remains a major contributor to the sector’s carbon footprint, especially when airfreight is used for rapid or temperature-sensitive deliveries. Cold chain logistics also require energy-intensive refrigeration for temperature-sensitive products like biologics, vaccines, and gene therapies. The rise in customs delays, which prolong shipping timelines or require rerouting, only compounds the problem. Prolonged storage and energy use in warehousing, re-cooling, or last minute re-shipping all contribute to additional emissions. Additionally, waste from single-use packaging contributes to the environmental footprint throughout the entire supply chain. The initial costs of investing in reusable materials and establishing the necessary infrastructures can be prohibitive. Furthermore, regulations around pharmaceutical transport and hygiene make adopting reusable packaging complex. Infrastructure disparities between regions, inconsistent customs requirements, and varying environmental regulations all add compounded friction to sustainable initiatives.
In response to these challenges, efforts toward innovations are emerging. For example, key impact areas include transitioning to energy-efficient vehicles, optimising delivery routes, and adopting alternative fuels. Improvements in insulation, energy-efficient cooling systems, and the use of renewable energy sources for cold-chain logistics can significantly reduce the carbon footprint for these operations. Lastly, reusable packaging advanced tracking systems and predictive analytics will play a key role in minimising waste, ensuring that sustainable practices are embedded into every step of the supply chain. This begins with an understanding of the full supply chain and mapping out all the areas that might uncover hidden environmental impacts from upstream suppliers to waste generated during production.
To address the hurdles of customs delays, which also impact sustainability, it is important to streamline documentation processes through digitisation, reducing time required for customs clearance. This can also include pre-clearance agreements with customs authorities and establishing strong partnerships with customs brokers and regulatory bodies to further expedite this process to ensure timely deliveries while minimising environmental impact.
Regulatory Compliance
As global operations expand, regulatory complexity increases. Life sciences companies must ensure compliance not only with local health authorities but also with international customs, tax, and safety rules.
Different countries require different documentation, certifications, and classification systems for pharmaceutical goods. Errors or omissions can result in shipment delays, customs seizures, or financial penalties. For cold chain products or complex medicines, such as Cell Gene Therapies with short shelf lives, these setbacks can be disastrous.
Advanced tracking and temperature monitoring are no longer optional. They are essential for compliance, especially for high-risk, high-value products. Logistics providers must now offer end-to-end visibility and robust quality control systems to support both product integrity and regulatory assurance.
It’s Not All Bad News
The logistics challenges currently facing the life sciences sector are complex, intertwined, and constantly evolving. From geopolitical tensions and economic volatility to regulatory pressures and sustainability goals, the demands on supply chains are greater than ever. Despite the many challenges, however, the life sciences logistics sector remains a place of remarkable innovation, purpose, and transformation. While it is difficult to predict the political and economic future with certainty, the ability of the logistics sector to adapt through addressing key areas of impact with technology, collaboration, and thoughtful investment gives reason for optimism and will be central to the life sciences sector’s continued success.
Vincent Howard is the CEO of Biocair and brings extensive experience in global operations and sales. He has built strong client relationships by delivering tailored logistics solutions. Vincent believes that customer service begins with care for the people you work alongside, a principle that extends to how Biocair serves its clients and, ultimately, the patients at the end of every shipment.
